<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883515</url>
  </required_header>
  <id_info>
    <org_study_id>2019/0334/HP</org_study_id>
    <nct_id>NCT04883515</nct_id>
  </id_info>
  <brief_title>Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.</brief_title>
  <acronym>OBEGLUT</acronym>
  <official_title>Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered&#xD;
      glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients&#xD;
      and lead to reduce the quality of life. In the last decades, the role of gut microbiota and&#xD;
      intestinal permeability has been underlined in obesity, glycemic control and IBS.&#xD;
      Interestingly, experimental and clinical data show that glutamine, an amino acid, is able to&#xD;
      maintain or restore intestinal permeability in different conditions. We thus hypothesize that&#xD;
      oral glutamine supplementation may restore gut barrier function contributing to improve&#xD;
      glycemic control and IBS-symptoms. Our project will thus aim to evaluate the effects of 8&#xD;
      weeks - oral glutamine supplementation on glycemic control and IBS symptoms in obese patients&#xD;
      in a blinded randomized controlled trial. Placebo group will received protein powder. 55&#xD;
      obese patients will enrolled in each arm and will received oral glutamine supplementation or&#xD;
      protein powder (10g t.i.d.) during 8 weeks. Blood and feces samples and intestinal&#xD;
      permeability assays will be performed at baseline (w0), after 8 weeks of supplementation (w8)&#xD;
      and then after 8 weeks of a wash-out period (w16).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change between Homeostasic model assessment of insulin resistance test value at baseline and week 8</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change between Homeostasic model assessment of insulin resistance test value at baseline and week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between Homeostasic model assessment of insulin resistance test value at Week 8 and week 16</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Francis score will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Francis score will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between feces consistency at baseline and week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>bristol scale will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between feces consistency at baseline and week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>bristol scale will be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Oral glutamine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral protein powder supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral glutamine supplementation</intervention_name>
    <description>patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks</description>
    <arm_group_label>Oral glutamine supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral protein powder supplementation</intervention_name>
    <description>patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks</description>
    <arm_group_label>Oral protein powder supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Insulin-resistance evaluation</intervention_name>
    <description>Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16</description>
    <arm_group_label>Oral glutamine supplementation</arm_group_label>
    <arm_group_label>Oral protein powder supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional intestinal disorders evaluation</intervention_name>
    <description>Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16</description>
    <arm_group_label>Oral glutamine supplementation</arm_group_label>
    <arm_group_label>Oral protein powder supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 18 to 65 years&#xD;
&#xD;
          -  Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2)&#xD;
&#xD;
          -  Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et &lt; 1.26 g/l)&#xD;
&#xD;
          -  Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with Known liver insufficiency (prothrombin time &lt; 70%)&#xD;
&#xD;
          -  Patient with Known kidney failure (GFR &lt; 60 ml/mn)&#xD;
&#xD;
          -  Patient with Known intestinal diseases such as inflammatory bowel diseases&#xD;
&#xD;
          -  Vomiting patients (≥ 1/ day) during the last 4 weeks&#xD;
&#xD;
          -  Patient Previously received bariatric surgery or digestive surgery&#xD;
&#xD;
          -  Patient Using laxatives or protein powder during the 4 last weeks&#xD;
&#xD;
          -  On going Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène LELANDAIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moïse COEFFIER, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène LELANDAIS, MD</last_name>
    <phone>+3323288</phone>
    <phone_ext>9065</phone_ext>
    <email>helene.lelandaix@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hélène LELANDAIS, MD</last_name>
      <phone>+3323288</phone>
      <phone_ext>9065</phone_ext>
      <email>helene.lelandais@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène LELANDAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa FOLOPE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral glutamine supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

